Deals

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035
ADC / XDCAdlai Nortye

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

Adlai Nortye (NASDAQ: ANL) announced that it has separately entered into clinical trial collaboration and drug supply agreements with Eli Lilly and Company (NYSE: LLY) and Merck KGaA, Darmstadt, Germany…

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Tigermed Acquires Japan's Micron CRO to Expand Imaging Expertise in Asia-Pacific
HKG: 3347Micron

Tigermed Acquires Japan’s Micron CRO to Expand Imaging Expertise in Asia-Pacific

Shanghai Biomedicine M&A Fund Acquires Stake in MicroPort via Share Transfer Agreement
FinanceHKG: 0853

Shanghai Biomedicine M&A Fund Acquires Stake in MicroPort via Share Transfer Agreement

BMS and Bain Capital Launch New Autoimmune Disease Focused Biopharma Company
Auto-immuneBMS

BMS and Bain Capital Launch New Autoimmune Disease Focused Biopharma Company

Tibet Aim Pharm's Major Shareholder Transfers Stake to Beijing Fuhao
FinanceSHE: 002826

Tibet Aim Pharm’s Major Shareholder Transfers Stake to Beijing Fuhao

Show More